Free Trial

Fortress Biotech (FBIO) Competitors

$1.88
+0.05 (+2.45%)
(As of 09:44 AM ET)

FBIO vs. BOLT, CMRX, RGLS, JAGX, VYNE, EYEN, DRRX, UNCY, LEXX, and CARA

Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Bolt Biotherapeutics (BOLT), Chimerix (CMRX), Regulus Therapeutics (RGLS), Jaguar Health (JAGX), VYNE Therapeutics (VYNE), Eyenovia (EYEN), DURECT (DRRX), Unicycive Therapeutics (UNCY), Lexaria Bioscience (LEXX), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical preparations" industry.

Fortress Biotech vs.

Bolt Biotherapeutics (NASDAQ:BOLT) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.

Fortress Biotech has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bolt Biotherapeutics$11.32M2.61-$69.20M-$1.66-0.47
Fortress Biotech$85.11M0.43-$60.64M-$6.10-0.30

Fortress Biotech received 244 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 65.57% of users gave Bolt Biotherapeutics an outperform vote while only 64.80% of users gave Fortress Biotech an outperform vote.

CompanyUnderperformOutperform
Bolt BiotherapeuticsOutperform Votes
80
65.57%
Underperform Votes
42
34.43%
Fortress BiotechOutperform Votes
324
64.80%
Underperform Votes
176
35.20%

In the previous week, Bolt Biotherapeutics had 6 more articles in the media than Fortress Biotech. MarketBeat recorded 13 mentions for Bolt Biotherapeutics and 7 mentions for Fortress Biotech. Bolt Biotherapeutics' average media sentiment score of 0.67 beat Fortress Biotech's score of 0.04 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bolt Biotherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fortress Biotech
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bolt Biotherapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.

Bolt Biotherapeutics presently has a consensus price target of $3.50, suggesting a potential upside of 351.90%. Fortress Biotech has a consensus price target of $30.00, suggesting a potential upside of 1,530.43%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Bolt Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bolt Biotherapeutics
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Fortress Biotech
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Fortress Biotech has a net margin of -69.13% compared to Fortress Biotech's net margin of -556.59%. Fortress Biotech's return on equity of -51.74% beat Bolt Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bolt Biotherapeutics-556.59% -51.74% -37.70%
Fortress Biotech -69.13%-770.86%-35.47%

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 30.9% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 33.4% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Fortress Biotech beats Bolt Biotherapeutics on 13 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBIO vs. The Competition

MetricFortress BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$36.65M$6.93B$5.06B$8.00B
Dividend YieldN/A2.55%2.84%3.92%
P/E Ratio-0.3022.62169.6518.43
Price / Sales0.43282.952,522.4977.09
Price / CashN/A25.6736.2931.80
Price / Book-9.205.875.414.56
Net Income-$60.64M$146.62M$105.04M$213.99M
7 Day Performance4.55%-2.62%-2.17%-1.60%
1 Month Performance1.66%0.49%1.70%2.25%
1 Year Performance-76.84%-8.95%3.48%6.18%

Fortress Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BOLT
Bolt Biotherapeutics
2.5526 of 5 stars
$0.78
-2.5%
$3.50
+351.6%
-60.3%$29.55M$7.88M-0.47100High Trading Volume
CMRX
Chimerix
3.923 of 5 stars
$0.98
-1.0%
$8.00
+720.5%
-34.1%$87.39M$320,000.00-1.0572Analyst Downgrade
RGLS
Regulus Therapeutics
2.7582 of 5 stars
$1.89
-6.0%
$7.25
+283.6%
+40.1%$131.59MN/A-1.2930
JAGX
Jaguar Health
0.237 of 5 stars
$0.14
-17.4%
N/A-88.5%$39.39M$9.76M0.0049Analyst Forecast
Stock Split
News Coverage
Gap Up
VYNE
VYNE Therapeutics
3.2076 of 5 stars
$2.70
-1.1%
$5.75
+113.0%
-64.4%$39.23M$420,000.00-0.5010Gap Up
EYEN
Eyenovia
1.2175 of 5 stars
$0.74
flat
$10.00
+1,256.5%
-77.5%$39.71MN/A-0.9857Gap Down
DRRX
DURECT
3.3527 of 5 stars
$1.29
+24.0%
$27.50
+2,031.8%
-79.7%$40.04M$8.55M-1.3658Analyst Upgrade
High Trading Volume
UNCY
Unicycive Therapeutics
2.0379 of 5 stars
$1.03
-2.8%
$5.30
+414.6%
-30.8%$38.74M$680,000.00-0.8712Gap Down
LEXX
Lexaria Bioscience
2.2484 of 5 stars
$2.99
+2.4%
$12.00
+301.3%
+269.0%$38.53M$404,726.00-4.405Gap Down
CARA
Cara Therapeutics
3.598 of 5 stars
$0.75
flat
$11.12
+1,375.2%
-80.2%$41.22M$20.97M-0.3455Analyst Forecast
Gap Down

Related Companies and Tools

This page (NASDAQ:FBIO) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners